Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.
News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.
Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.
This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leader in diabetes technology, will present a company update at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022, at 9:00 AM Eastern Time. The presentation will be available via live webcast, and an archive will be accessible for 30 days. More details can be found on Tandem's Investor Center under the “Events & Presentations” section. Tandem is known for its innovative insulin delivery solutions, including the t:slim X2 insulin pump.
Tandem Diabetes Care reported its Q3 2022 results, highlighting a 35% increase in its worldwide installed customer base, surpassing 400,000. Total sales rose 14% to $204.5 million, driven by a nearly 70% surge in U.S. renewal pump shipments. Despite a gross profit increase of 8% to $104.4 million, the company faced a GAAP net loss of $49 million, compared to a profit in the prior year. The updated 2022 guidance estimates non-GAAP sales between $800 million and $805 million, down from previous expectations, amid cautious market conditions.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present updates at several investor conferences in November 2022. The presentations will take place at the Credit Suisse 31st Annual Healthcare Conference on November 8 at 4:25 PM ET, the Jefferies London Healthcare Conference on November 15 at 12:20 PM GMT, and the Stifel 2022 Healthcare Conference on November 16 at 4:45 PM ET. All presentations will be webcast live with an archive available for 30 days on their Investor Center website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) plans to announce its third quarter 2022 results post-market close on November 2, 2022. A conference call and webcast, scheduled for 4:30 PM ET, will discuss the financial and operational results. Investors can access the live webcast via the Investor Center on their website. An archived version will be available for 30 days following the event.
As a prominent insulin delivery and diabetes technology firm, Tandem continues to innovate with products like the t:slim X2 insulin pump featuring Control-IQ technology.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present at two upcoming investor conferences: the Wells Fargo Healthcare Conference on September 8, 2022, at 1:55 PM ET and Baird’s Global Healthcare Conference on September 13, 2022, at 9:40 AM ET. Both presentations will be webcast live, with archived recordings available for 30 days on their Investor Center website. Tandem focuses on innovative diabetes solutions, offering products like the t:slim X2 insulin pump with Control-IQ technology.
Tandem Diabetes Care (NASDAQ:TNDM) announced that users of its t:slim X2 insulin pump have delivered over 1 million insulin boluses via the t:connect app within a month of its launch. This app, the first FDA-cleared one for initiating insulin delivery on smartphones, supports both iOS and Android on approximately 30 devices. Users can activate this feature at no additional cost. CEO John Sheridan emphasized the importance of innovative technology for improving diabetes management.
Tandem Diabetes Care (NASDAQ: TNDM) reported strong Q2 2022 results, with worldwide sales up 16% to $200.3 million and a 40% increase in its installed base, totaling over 375,000 customers. U.S. sales rose 14% to $145.7 million, and gross profit increased 10% to $101.9 million. However, the company updated its 2022 sales guidance down to $835 million - $845 million, lower than previous estimates. Furthermore, a net loss of $15.1 million was reported compared to a $4.0 million income in the same quarter last year. Adjusted EBITDA also saw a decline.
Tandem Diabetes Care (NASDAQ:TNDM) has acquired Capillary Biomedical, an infusion set developer, aiming to enhance its insulin delivery portfolio. The acquisition focuses on expanding options for insulin pump wearability, with a commitment to developing innovative solutions that extend wear time and reduce user burden. Although the technology is still in development and not yet available commercially, the company sees potential synergies in integrating Capillary's solutions into its product offerings. Financial terms of the transaction remain undisclosed.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its second quarter 2022 results on August 3, 2022, after market close. A conference call will follow at 4:30 PM ET to discuss financial and operating results. The event will be accessible via webcast on the company's Investor Center website, with an archive available for 30 days post-event. Tandem is dedicated to enhancing the lives of those living with diabetes through innovative insulin delivery solutions, such as the t:slim X2 insulin pump.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced the appointment of Myoung Cha and Joao Malagueira as independent directors, effective June 15, 2022. John Sheridan, CEO, highlighted their extensive experience as valuable assets for the company's global expansion and product development. Cha brings over 17 years in healthcare, previously at Apple and McKinsey & Company. Malagueira has 25 years in diabetes and medical devices, currently at Hologic, with a strong record in EMEA markets. Their leadership is expected to strengthen Tandem's strategic direction.